Skip to main content

Advertisement

Log in

Frangulosid as a novel hepatitis B virus DNA polymerase inhibitor: a virtual screening study

  • Original Research
  • Published:
In Silico Pharmacology Aims and scope Submit manuscript

Abstract

Hepatitis B virus (HBV) infects more than 400 million humans Worldwide. Currently, development of new anti-HBV agents is focused on inhibiting of HBV DNA polymerase activity. The natural components of medicinal plant have a broad spectrum of biological activities with therapeutic properties which can be exploited in various steps of drug discovery. Currently, in silico analyses have been introduced as alternative or supplements methods for drug discovery. This study was planned to in silico screening novel HBV DNA polymerase inhibitor(s) from R. palmatum, R. coreanus and S. officinalis. For this purpose, a set of dominant phytochemicals from mentioned plants were retrieved from PubChem database and primary screening was performed with molecular docking method using iGemdock 2.1 software. SwissADME and MedChem Designer 3.0 were used to calculate the drug-likeness parameters of the ligands. Furthermore, the genotoxicity of the studied ligands was predicted using Toxtree 2.6.6 software. Final analysis of screened compounds was done using Autodock 4 software. Result confirmed that Frangulosid and Lindleyin acid have most and least efficacy in HBV DNA polymerase inhibition with the inhibition constant of 2.97 and 53.83 µM, respectively. Results also showed that, the amino acids, involved in interaction, were different for each compound. In this regards, results revealed that the main amino acids residues of the receptor, involved in interaction with Quercetin-3-glucuronide, Frangulosid and Lindleyin separately, located in 420–424, 606–615 and 512–542 spectra, respectively. In conclusion, Frangulosid can be considered as a good candidate for more investigation of its anti-HBV activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Ahmad A, Ahad A, Rao AQ, Husnain T (2015) Molecular docking based screening of neem-derived compounds with the NS1 protein of Influenza virus. Bioinformation 11:359

    Article  PubMed  PubMed Central  Google Scholar 

  • Bonifácio BV, da Silva PB, dos Santos Ramos MA, Negri KMS, Bauab TM, Chorilli M (2014) Nanotechnology-based drug delivery systems and herbal medicines: a review. Int J Nanomed 9:1

    Article  Google Scholar 

  • Byler KG, Ogungbe IV, Setzer WN (2016) In-silico screening for anti-Zika virus phytochemicals. J Mol Graph Model 69:78–91

    Article  CAS  PubMed  Google Scholar 

  • Chemin I, Zoulim F (2009) Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 286:52–59

    Article  CAS  PubMed  Google Scholar 

  • Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E (2001) Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 75:4771–4779

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dibyajyoti S, Bin ET, Swati P (2013) Bioinformatics: the effects on the cost of drug discovery. Galle Med J 18:44–50

    Article  Google Scholar 

  • Ganem D, Prince AM (2004) Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 350:1118–1129

    Article  CAS  PubMed  Google Scholar 

  • Jain J, Kumari A, Somvanshi P, Grover A, Pai S, Sunil S (2017) In silico analysis of natural compounds targeting structural and nonstructural proteins of chikungunya virus. F1000Research 6:1601

    Article  PubMed  PubMed Central  Google Scholar 

  • Jones SA, Clark DN, Cao F, Tavis JE, Hu J (2014) Comparative analysis of hepatitis B virus polymerase sequences required for viral RNA binding, RNA packaging, and protein priming. J Virol 88:1564–1572

    Article  PubMed  PubMed Central  Google Scholar 

  • Kandagalla S, Sharath B, Bharath BR, Manjunatha H (2016) Molecular docking analysis of curcumin analogues against kinase domain of ALK5. In Silico Pharmacol 5:15

    Article  Google Scholar 

  • Khan MTH, Ather A, Thompson KD, Gambari R (2005) Extracts and molecules from medicinal plants against herpes simplex viruses. Antiviral Res 67:107–119

    Article  CAS  PubMed  Google Scholar 

  • Kim TG, Kang SY, Jung KK, Kang JH, Lee E, Han HM, Kim SH (2001) Antiviral activities of extracts isolated from Terminalis chebula Retz., Sanguisorba officinalis L., Rubus coreanus Miq. and Rheum palmatum L. against hepatitis B virus. Phytother Res 15:718–720

    Article  CAS  PubMed  Google Scholar 

  • Kim K-H, Kim ND, Seong B-L (2010) Discovery and development of anti-HBV agents and their resistance. Molecules 15:5878–5908

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kurokawa M et al (1999) Anti-herpes simplex virus activity of moronic acid purified from Rhus javanica In vitro and in vivo. J Pharmacol Exp Ther 289:72–78

    CAS  PubMed  Google Scholar 

  • Langley DR et al (2007) Inhibition of hepatitis B virus polymerase by entecavir. J Virol 81(8):3992–4001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 11:97–107

    Article  CAS  Google Scholar 

  • Lin X, Zhang S, Huang Q, Zheng L, Huang J, Zhang X, Huang R (2013) Anti-hepatitis B virus activity of total saponins isolated from Taraphochlamys affinis in vitro and in vivo. J Med Plants Res 7:2841–2846

    CAS  Google Scholar 

  • Lok AS, McMahon BJ (2009) Chronic hepatitis B: update. Hepatology 50:661–662

    Article  PubMed  Google Scholar 

  • Lu F, Zhuang H (2009) Management of hepatitis B in China. Chin Med J (Engl) 122:3–4

    Google Scholar 

  • Mak L-Y, Seto W-K, Lai C-L, Yuen M-F (2016) DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. Expert Opin Drug Saf 15:383–392

    Article  CAS  PubMed  Google Scholar 

  • Mekha Mohan PJ, Valsalan R, Nazeem PA (2015) Molecular docking studies of phytochemicals from Phyllanthus niruri against hepatitis B DNA polymerase. Bioinformation 11:426

    Article  PubMed  PubMed Central  Google Scholar 

  • Meng F-C, Xu W-R, Li Y-Z, Huang Z-M, Liang G-Y, Liu C-X (2015) In silico molecular docking study of repensine and bentysrepinine against HBV DNA polymerase. Chin Herb Med 7:39–44

    Article  CAS  Google Scholar 

  • Michel M-L, Deng Q, Mancini-Bourgine M (2011) Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 54(6):1286–1296

    Article  CAS  PubMed  Google Scholar 

  • Mukhtar M, Arshad M, Ahmad M, Pomerantz RJ, Wigdahl B, Parveen Z (2008) Antiviral potentials of medicinal plants. Virus Res 131:111–120

    Article  CAS  PubMed  Google Scholar 

  • Muzaffer U, Paul V, Prasad NR (2016) Molecular docking of selected phytoconstituents with signaling molecules of ultraviolet-B induced oxidative damage. In Silico Pharmacol 5:17

    Article  Google Scholar 

  • Nassal M, Schaller H (1993) Hepatitis B virus replication. Trends Microbiol 1:221–228

    Article  CAS  PubMed  Google Scholar 

  • Neuveut C, Wei Y, Buendia MA (2010) Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 52:594–604

    Article  CAS  PubMed  Google Scholar 

  • Noordeen F (2015) Hepatitis B virus infection: an insight into infection outcomes and recent treatment options. Virusdisease 26:1–8

    Article  PubMed  PubMed Central  Google Scholar 

  • Shaw T, Mok SS, Locarnini SA (1996) Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir. Hepatology 24:996–1002

    Article  CAS  PubMed  Google Scholar 

  • Shin MS, Kang EH, Lee YI (2005) A flavonoid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes. Antiviral Res 67:163–168

    Article  CAS  PubMed  Google Scholar 

  • Siddiqui MH, Alamri SA, Al-Whaibi MH, Hussain Z, Ali HM, El-Zaidy ME (2017) A mini-review of anti-hepatitis B virus activity of medicinal plants. Biotechnol Biotechnol Equip 31:9–15

    Article  CAS  Google Scholar 

  • Soltan MM, Zaki AK (2009) Antiviral screening of forty-two Egyptian medicinal plants. J Ethnopharmacol 126:102–107

    Article  PubMed  Google Scholar 

  • Suri SS, Fenniri H, Singh B (2007) Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2:16

    Article  PubMed  PubMed Central  Google Scholar 

  • Utsunomiya T, Kobayashi M, Herndon DN, Pollard RB, Suzuki F (1995) Glycyrrhizin (20β-carboxy-11-oxo-30-norolean-12-en-3β-yl-2-O-β-d-glucopyranuronosyl-α-d-glucopyranosiduronic acid) improves the resistance of thermally injured mice to opportunistic infection of herpes simplex virus type 1. Immunol Lett 44:59–66

    Article  CAS  PubMed  Google Scholar 

  • Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, Tajik H, Abubakar S, Zandi K (2014) A review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed Res Int 2014:186864. https://doi.org/10.1155/2014/186864

    Article  CAS  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge the University of Isfahan for the financial support of this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mokhtar Nosrati.

Ethics declarations

Conflict of interest

The authors have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 28 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nosrati, M., Shakeran, Z. & Shakeran, Z. Frangulosid as a novel hepatitis B virus DNA polymerase inhibitor: a virtual screening study. In Silico Pharmacol. 6, 10 (2018). https://doi.org/10.1007/s40203-018-0047-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40203-018-0047-3

Keywords

Navigation